Intellia Therapeutics

211 articles about Intellia Therapeutics

• Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

  10/3/2023

  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.

• Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

  8/3/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the second quarter ended June 30, 2023.

• Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

  7/27/2023

  Intellia Therapeutics, Inc. will present its second quarter 2023 financial results and operational highlights in a conference call on August 3, 2023, at 8 a.m. ET.

• 

  CRISPR on the Cusp: The Promise and the Pain Points

  7/10/2023

  Gene editing technologies are advancing rapidly in the clinic, with the potential first approval later this year, but challenges remain.

• Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

  6/11/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002.

• Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

  6/5/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023.

• Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

  5/31/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the acceptance of a late-breaking abstract from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study for a presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023, taking place June 9-11 in Hamburg, Germany, and virtually.

• Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

  5/4/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

• Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

  5/1/2023

  Intellia Therapeutics, Inc. today released its 2023 Corporate Responsibility report.

• Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

  4/27/2023

  Intellia Therapeutics, Inc. will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.

• Intellia Therapeutics Names Bill Chase to its Board of Directors

  4/17/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the appointment of Bill Chase, MBA, to its board of directors.

• 

  Gene Editing Therapeutics Could Hit the Market in 2023

  4/10/2023

  Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.
• 

  Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach

  4/4/2023

  With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases with an eye toward broader patient populations.

• Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

  3/21/2023

  Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).

• Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002

  3/2/2023

  Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).

• 

  Novartis Drops SCD Gene Therapy Program with Intellia

  2/23/2023

  Novartis has abandoned its ex vivo sickle cell disease program developed using Intellia Therapeutics’ CRISPR gene editing platform, Intellia announced Thursday.

• Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

  2/23/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.

• Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

  2/16/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.

• Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

  1/11/2023

  Intellia Therapeutics, Inc. today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE).

• 

  Intellia Pushes NTLA-2001 Gene Editing Therapy to the Fore of Near-Term Priorities

  1/6/2023

  Intellia Therapeutics released its strategic priorities for 2023-2024 Thursday, with a heavy emphasis on advancing its lead asset NTLA-2001 as a potential functional cure therapy for ATTR amyloidosis.